Figure 3.
Efficacy of aptamers and their combined treatment with erlotinib and/or PHA-665752 in HCC827/ER cells. Cells were treated with an aptamer (400 nM), erlotinib (1 µM), or PHA-665752 (1 µM), separately, or in a combination of aptamer (400 nM) with erlotinib (1 µM) and/or PHA-665752 (1 µM). Cell viability was measured using the CCK-8 assay. Results are representative of at least 3 independent experiments, and the error bars signify standard deviations (± SD).